AI Tools for FDA Medical Device Submissions: What Works, What Doesn't, and How to Use Them Safely
- Beng Ee Lim
- 4 hours ago
- 13 min read
AI tools can speed up specific parts of FDA medical device regulatory work, especially first-pass predicate research, guidance discovery, requirements checklists, gap spotting, and first-draft writing. The biggest risk is accuracy: general-purpose LLMs can generate confident text with false facts or hallucinated citations, so you should treat them as drafting and research assistants, not as sources of truth. Specialized regulatory platforms like Complizen reduce verification friction by grounding work in FDA datasets and attaching source-linked citations so teams can audit claims quickly.
AI does not replace regulatory judgment. Use it to accelerate research and generate structured drafts, then require human review for regulatory strategy, risk-based decisions, and final submission content.
Why AI Matters for FDA Regulatory Work
FDA medical device submissions require heavy regulatory research, document review, and structured technical writing. In practice, a 510(k) can easily become hundreds of pages of evidence and attachments, which is why teams often spend significant time just finding the right precedents, guidance, and requirements before they even start drafting.
Common workflow bottlenecks include:
predicate research across FDA clearance databases
interpreting FDA guidance
mapping device specs to expected evidence
assembling submission-ready sections in structured formats like eSTAR
The friction is rarely “lack of intelligence,” it’s the time spent navigating fragmented sources and translating them into a defensible submission narrative.
AI tools help most when they accelerate repeatable, text-heavy work, such as first-pass predicate shortlisting, pulling relevant guidance excerpts, organizing requirements checklists, and drafting early versions of submission sections.
FDA itself has also been actively shaping how AI-enabled device changes should be managed in submissions through its Predetermined Change Control Plan (PCCP) guidance. FDA issued a draft PCCP guidance in 2023 and later published/issued the guidance (see FDA guidance page and Federal Register notice), reflecting how AI/ML is becoming a core part of device lifecycle planning and regulatory documentation.
For international manufacturers, the impact is often even bigger. Teams with CE Mark experience may be less familiar with the FDA’s predicate-based “substantial equivalence” logic, and AI-assisted search can help them systematically explore product codes, similar clearances, and predicate patterns, as long as every candidate predicate and claim is verified against FDA sources.
What AI Can Do for FDA Submissions: High-Value Use Cases
Predicate device research
AI-assisted search is most valuable when it uses structured FDA clearance data, not just keyword guessing. Instead of searching by device name alone, strong tools can filter and cluster 510(k) records by product code, indications for use, and technological characteristics, which helps surface predicate candidates even when naming conventions differ.
Some tools pull 510(k) clearance data via public datasets such as openFDA’s device 510(k) endpoint, then layer semantic search and comparison on top. This can accelerate first-pass predicate shortlisting and help teams map how similar devices positioned substantial equivalence, but final predicate selection still requires expert judgment and primary-source verification.
What to watch out for: general-purpose AI, when not grounded in FDA sources, can fabricate device names, 510(k) numbers, and citations. Treat any non-cited answer as a draft hypothesis until verified.
FDA guidance document search
FDA publishes a large volume of device-related guidance, and relevant requirements for one device often span multiple documents. AI can help by searching across this guidance corpus using device characteristics, then extracting the most relevant sections for your submission plan.
Higher-quality tools do two things well:
They keep guidance retrieval tied to the official FDA guidance library.
They organize outputs into submission-ready buckets, like labeling, software documentation, biocompatibility, performance testing, and clinical evidence, so you can build a defensible checklist.
510(k) gap analysis and substantial equivalence tables
Gap analysis is where AI can save serious effort. Strong systems can take your device specs, predicate summaries, and relevant guidance excerpts, then generate a structured comparison across dimensions like intended use, technological characteristics, materials, energy source, operating principle, and performance testing.
AI is best at:
Finding differences and organizing them into a table
Highlighting “likely-to-matter” areas for human review
AI is not reliable as the final judge of regulatory significance. Humans decide whether a difference is acceptable, how to justify it, and what testing is required.
Regulatory document review and completeness checking
Technical reports like biocompatibility, electrical safety, performance testing, and clinical documentation can be long and dense.
AI is useful for:
Extracting key results and conditions
Summarizing test setup, acceptance criteria, and conclusions
Pulling tables into structured formats to reduce transcription errors
AI can also help flag missing elements, but it should be checking against your stated endpoint plan and regulatory strategy, not a generic “ISO requires everything” checklist.
Submission drafting assistance aligned to eSTAR structure
eSTAR is FDA’s interactive template used to prepare a comprehensive submission, and it enforces structure through prompts and required sections. AI can draft text aligned to eSTAR section headings, for example device description, indications for use language, testing summaries, and substantial equivalence comparison tables.
Where AI helps most:
Creating first drafts fast
Standardizing tone and structure across sections
Producing consistent comparison tables and summaries
Where humans must stay in control:
Regulatory strategy and positioning
Final accuracy and source verification
Nuanced claims that depend on predicate selection and risk rationale
What AI Cannot Do for FDA Submissions: Where Humans Must Stay in Control
AI is useful for accelerating research and drafting, but there are categories of work where AI should never be the decision-maker. These areas require regulatory accountability, risk tradeoffs, and domain experience.
Regulatory strategy decisions (510(k) vs De Novo vs PMA)
Choosing the right pathway depends on device classification, predicate availability, technological differences, and how FDA has treated similar devices in the past. AI can help surface comparable devices and summarize references, but the final pathway decision should be owned by an experienced regulatory professional.
Q-Sub and Pre-Submission strategy
Pre-Submission (Q-Sub) work is high leverage. It includes deciding when to engage FDA, what questions to ask, how to frame your device and evidence plan, and how to avoid locking yourself into a weak position too early. AI can help draft question sets and background summaries, but humans must choose the strategy.
Responding to FDA requests for additional information
Deficiency and Additional Information responses require careful risk management: you must answer the question, avoid introducing new claims, and select evidence that strengthens the submission without creating new vulnerabilities. AI can help draft responses and organize supporting documents, but experienced reviewers should control the final content.
Novel devices and complex classification scenarios
For first-in-class devices, combination products, or devices that could plausibly fit multiple product codes, uncertainty is higher and the cost of a wrong call is much larger. AI can brainstorm analogs and summarize similar cases, but it is more likely to be wrong in novel situations, so expert oversight is essential.
Clinical evidence and trial design strategy
Whether you need clinical data, and how to design a study if you do, is a multi-factor decision that depends on device type, risk profile, claims, available benchmarks, and FDA expectations. AI can assist with literature collection and drafting, but protocol decisions must be owned by qualified clinical, statistical, and regulatory experts.
High-stakes FDA communication and post-market events
Recall classification, recall strategy, and public communications are high-stakes and legally sensitive. AI can help draft communications, but execution requires coordinated decision-making across RA/QA, legal, and FDA communications, using FDA recall policy as the anchor.
AI Tool Landscape: General-Purpose vs Specialized Regulatory AI
General-Purpose AI (ChatGPT, Claude, Perplexity)
✅ Strengths
Fast summarization and drafting: Great for turning long documents into structured summaries, extracting key points, and generating first drafts of internal notes and submission-language drafts.
Broad reasoning across domains: Useful for brainstorming, outlining, and translating technical content into clearer regulatory-ready language.
Web-first research (especially Perplexity): Perplexity is built around citations and web retrieval. ChatGPT can browse depending on plan/settings, which helps for checking the latest FDA guidance pages and announcements.
⚠️ Weaknesses
Not “source of truth” by default: Without grounded retrieval, general-purpose AI can produce confident statements with incorrect CFR citations, invented guidance titles, or fabricated 510(k) references. Your workflow must enforce verification against FDA primary sources.
Not inherently FDA-dataset-native: They can browse FDA webpages, but they don’t automatically behave like a structured FDA database tool unless you build that workflow. FDA clearance records and other datasets exist publicly, but you must validate everything at the source.
Staleness risk: Instead of quoting training cutoffs, the safe truth is: models can be outdated, and FDA guidance/standards status changes. Always verify against current FDA pages.
✅ Best use cases
Summarize long reports, extract key results and acceptance criteria
Draft internal memos, gap-check questions, and first-pass section outlines
Brainstorm Pre-Sub question sets and alternative wording (not final strategy)
🧯 Safety rules (non-negotiable)
Never accept regulatory citations unless you can click to the primary source (FDA page, eCFR text, openFDA record).
Never use general AI as the final authority for predicate selection, classification, or claims.
Specialized Regulatory AI: Complizen and Purpose-Built Tools
What “specialized” tools do differently: instead of generating generic text, they ground work in FDA records, attach citations, and organize outputs into submission-ready structure. That reduces verification friction and lowers the risk of fabricated citations compared with free-form chat alone.
Complizen is positioned as an AI workspace for FDA medical-device regulatory research and planning. It connects multiple FDA datasets into one workflow so teams can move from question to evidence faster, with answers traceable back to sources.
Key Complizen workflows
Predicate Intelligence and predicate tracking
Complizen’s predicate workflow is designed to help teams surface likely predicate candidates and compare them using FDA records, then validate the final predicate decision with human review. The value is not “auto-deciding your predicate,” it is making predicate research faster and more auditable.
Product code and classification context
Complizen presents device classification context, product codes, and related FDA materials in one place to support pathway and evidence planning. This helps teams avoid starting from a blank page, especially when classification is ambiguous or terminology differs across databases.
Tests and standards mapping
FDA’s recognized consensus standards database includes recognition scope, dates, and editions. Purpose-built tools can map standards to device context so teams catch likely testing expectations earlier, rather than discovering missing standards late in the submission cycle.
Risk and recall context
Post-market signals matter, even during premarket planning. Reviewing adverse event and recall patterns alongside predicate candidates can inform risk analysis and help teams understand common failure modes in a device category.
Submission planning workspace
Specialized platforms add value when they centralize evidence, drafts, and decisions. Complizen positions this as a workspace where teams can keep research, findings, and drafts together, and align work to structured submission sections such as eSTAR.
Differentiator that is defensible
The defensible differentiator is not “we never hallucinate.” It is auditability. Complizen emphasizes that work should be backed by FDA sources so users can verify quickly and keep a defensible trail from question to evidence.
You can also connect this to FDA’s push for more predictable predicate selection practices, where stronger, cleaner predicate rationale improves review quality.
Other categories of regulatory AI tools
Document compliance checking
These tools focus on format and completeness checks, for example template conformity and missing sections. They are helpful near the end of the workflow, but they do not replace predicate intelligence, evidence planning, or strategy.
Regulatory change monitoring
These tools track guidance updates, standards recognition changes, and new clearances. Useful for awareness, but not a full submission workflow.
QMS and post-market systems with AI features
These tools focus on complaint handling, MDR trend analysis, CAPA signals, and supplier quality. They help post-market compliance more than premarket submission building.
Risks and Limitations of AI in FDA Regulatory Work
Hallucination risk, invented FDA and ISO citations
The problem: General-purpose AI can produce confident regulatory citations, including FDA guidance titles, 21 CFR sections, ISO/IEC standards, and 510(k) numbers that are incorrect or entirely fabricated.
Example hallucinations (safe, verifiable):
A made-up CFR section like “21 CFR 860.95” is a red flag because Part 860’s actual section structure is publicly listed.
A made-up 510(k) number or device clearance claim should be validated in the official 510(k) database.
Why this happens: LLMs generate plausible text patterns. When they lack verified retrieval, they may produce “citation-shaped” answers that look real.
Mitigation checklist (must-follow):
✅ Verify FDA guidance on FDA pages, and confirm title and date match what AI claimed.
✅ Verify CFR citations in eCFR, and confirm the section exists and says what AI claims.
✅ Verify 510(k) numbers in the official 510(k) database.
✅ Verify FDA-recognized consensus standards in FDA’s standards database, including recognition scope and edition.
Tools like Complizen reduce verification friction by keeping regulatory work source-linked to FDA datasets, but you still need human review for interpretation and final decisions.
Staleness risk, missing recent FDA updates
The problem: AI responses can be outdated. FDA guidance, FDA-recognized standards, and 510(k) clearances change continuously, so you should assume any answer might miss the latest update unless it cites a current primary source.
Why it matters: 510(k) activity is high volume, published analyses show FDA clears roughly ~3,000 510(k)-track devices per year in recent years, so “new predicates” and trends appear constantly.
Mitigation:
✅ Cross-check any “latest guidance” claim on current FDA pages.
✅ Treat FDA’s recognized standards database as the live source of truth. It is updated as FDA recognizes standards, not on a fixed quarterly schedule.
Regulatory interpretation errors, confident but wrong
The problem: Even when citations are real, AI can misread nuance, especially around “may be necessary” versus “required,” edge-case classification, special controls, and substantial equivalence logic.
Mitigation:
✅ Human review for pathway, classification, and SE judgments, always.
✅ When the case is novel or ambiguous, use Q-Sub to confirm with FDA rather than relying on AI confidence.
Over-reliance, skipping expert review
The problem: Polished AI output creates false confidence. Teams may submit incomplete or strategically weak content because it “sounds right.”
Mitigation:
✅ Require documented sign-off for every AI-assisted section.
✅ Cross-functional validation: engineering for technical accuracy, QA for evidence completeness, RA for regulatory logic.
Data security and confidentiality risks
The problem: Uploading proprietary device specs, clinical data, or strategy into consumer AI tools can create confidentiality and compliance risk. Policies differ by provider and plan.
What the sources actually say:
OpenAI API data is not used to train models by default unless you opt in.
Anthropic states Claude chats may be used for training only if you opt in, otherwise default handling differs, and there are also safety-review cases.
Perplexity states enterprise user data is not used for training and uploaded file retention is limited, such as 7 days, depending on plan.
Mitigation (practical):
✅ Do not upload trade secrets or identifiable patient data into consumer tools.
✅ Use business or enterprise plans with stronger controls when you must process sensitive data. Verify the specific plan’s policy before upload.
✅ Redact identifiers and proprietary manufacturing details, and keep the “most sensitive” work offline.
Future of AI in FDA Medical Device Regulation (2025–2027)
FDA’s internal AI adoption for review support
FDA has publicly announced internal AI efforts, including a generative AI pilot for scientific reviewers and a broader push to scale AI tools across the agency. These tools are positioned to reduce repetitive work and free reviewers to focus on substantive scientific and regulatory judgment.
A concrete example already visible in the medical device submission workflow is eSTAR. FDA states that eSTAR automates many aspects of the submission to ensure required content is present and FDA does not intend to conduct a Refuse to Accept review for eSTAR submissions. For De Novo requests, FDA notes that the acceptance review under 21 CFR 860.230 has been largely automated within eSTAR, with technical screening and virus scanning still part of the process.
What this likely means for manufacturers: completeness and consistency checks will matter more, not less. Submissions that are clean, structured, and internally consistent will move faster through early screening, while sloppy submissions will be flagged earlier.
Expanded use of FDA datasets in regulatory intelligence tools
FDA already provides a large set of public device databases. The Total Product Life Cycle (TPLC) database integrates premarket and postmarket datasets and is designed to help users see device activity across the lifecycle, often organized by procode.
FDA also provides public establishment registration and listing search, updated weekly, which helps identify registered establishments and device listings.
For compliance and enforcement intelligence, FDA provides resources including warning letters and inspection-related datasets, such as the Inspection Classification Database, inspection observations summaries, and published 483 datasets.
2025–2027 forecast, clearly labeled: regulatory tools will likely get better at connecting these datasets into one place so teams can benchmark predicates, spot common failure modes, and plan evidence with fewer blind spots. These will be decision-support tools, not decision-makers.
AI-assisted Pre-Sub and Q-Sub preparation
Pre-Submissions and Q-Subs are still one of the highest leverage actions for risky or novel devices, because they let you test assumptions early.
Forecast: AI will increasingly help teams draft tighter Q-Sub packages by generating structured question lists, building comparison tables, and assembling supporting evidence into a reviewer-friendly format. It should not be framed as “predicting FDA’s response,” it is better framed as reducing prep effort while improving clarity.
Continuous regulatory monitoring moves from “nice-to-have” to standard practice
With frequent changes in guidance, standards recognition, and device activity, the obvious direction is continuous monitoring. FDA’s own sites, including eSTAR program pages and the standards database, are living resources that change over time.
Forecast: platforms will compete on who can provide the most relevant alerts with the least noise, for example standards updates that affect your product code, new recall patterns in your category, or new guidance pages that change documentation expectations.
What will not change, accountability and expert judgment
Even as AI improves, the manufacturer remains responsible for the submission’s accuracy and for the strategy behind claims, testing, and equivalence rationale. FDA’s own framing of AI tools is about assisting reviewers and reducing repetitive work, not replacing human decision-making.
The Fastest Path to Market
Frequently Asked Questions: AI for FDA Medical Device Submissions
Can I use ChatGPT to write my entire 510(k) submission?
Not safely. General AI is best for first drafts, summaries, and outlining, but every section must be validated by a qualified regulatory professional and verified against FDA primary sources.
What’s the difference between general AI and specialized regulatory AI?
General AI helps with language tasks and summarization, but it is not inherently grounded in verified FDA datasets. Specialized regulatory platforms focus on source-linked regulatory intelligence and structured workflows, which reduces verification friction for things like predicates, classification context, and standards mapping.
How do I verify AI-generated regulatory citations?
Use a hard rule: no citation is trusted until you can click to the primary source. Verify 510(k)s in FDA’s 510(k) database, verify eSTAR requirements on FDA’s eSTAR pages, and verify CFR text in eCFR.
Can AI select my predicate device for me?
AI can help shortlist candidates, but humans must decide the final predicate and strategy. Predicate choice is submission-defining and must be validated using official FDA clearance records and device details.
Will FDA accept an AI-assisted 510(k) submission?
FDA evaluates accuracy, completeness, and compliance, not whether you used AI. If AI was used, the manufacturer is still responsible for the content, and eSTAR is designed to help ensure submissions are complete.
What’s the biggest risk of using AI for regulatory work?
Hallucinations and confident misinterpretation. Treat AI as a drafting and research accelerator, and verify every claim against FDA sources before it reaches a submission.
Is my data secure if I upload device information to AI tools?
It depends on the provider and plan. OpenAI’s business products and API are not used for training by default unless you opt in, and there are user controls for personal ChatGPT data sharing. Anthropic’s commercial products state they don’t train on your inputs/outputs by default. Perplexity’s Enterprise documentation states enterprise data is not used for training and includes specific retention policies.
Will AI replace regulatory consultants or in-house RA teams?
No. AI can reduce time spent on repeatable research and drafting, but strategy, risk decisions, and FDA communication remain human work. Think “faster experts,” not “expert replacement.”
Can AI help with Pre-Sub and FDA deficiency responses?
Yes for drafting and organizing evidence, but humans must control strategy and final wording. eSTAR and FDA review workflows still expect complete, coherent submissions and responses that are technically correct.
